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 HIGHLIGHTS  
 First study providing data on AKASI after conventional PDT  
 Establishment of AKASI 50, 75, 100 as tool to easily compare treatment 
modalities  
 Significant differences between pre-treated and treatment naïve patients 
 
 
ABSTRACT  
Background Actinic keratosis area and severity index (AKASI) is a new quantitative 
tool for assessing AK severity on the head and can be used to monitor outcomes of 
different therapies. The aim of this study was to determine treatment outcomes of AK 
applying AKASI three months after conventional photodynamic therapy (PDT).  
Methods We performed a retrospective analysis of patients who have undergone PDT 
on the head and had a documented AKASI evaluation prior to PDT and at follow-up 
visits.  
Results Of the 33 patients included, 32 (97.0 %) patients showed an AKASI reduction 
and 1 (3.0%) patient an increase of AKASI at follow-up visits compared to baseline. 
The median (range) follow-up period was 96 days (70-161). The median difference of 
AKASI values between both visits was 73.7% (-34.8-100.0%). The Wilcoxon test 
showed highly significant differences (P < 0.0001) between visits. 14 (42.4%) patients 
showed an AKASI 100 (complete clearance), 16 (48.5%) an AKASI 75 and 24 (72.7%) 
an AKASI 50, respectively. 
The Mann-Whitney U test showed in a subgroup analysis of patients with a positive 
history of at least more than one intervention and treatment naïve patients significant 
differences in these two groups (P = 0.0302). 
Conclusions AKASI represents a feasible and comparable tool for objectively 
assessing field-directed treatment modalities such as PDT in daily routine. The 
establishment of AKASI 50, 75, 100 serves as an objective measure to compare 
treatment outcomes to baseline severity of AK.   
  
INTRODUCTION 
Actinic keratoses (AK) are commonly located on UV-damaged skin sites and present 
as erythematous macules, keratotic patches or plaques.[1] They are regarded as early 
in-situ squamous cell carcinoma (SCC) and the risk of a single AK lesion to progress 
into an invasive SCC ranges between 0.025 to 16% per year.[2, 3] Due to changed 
leisure activities and an ongoing demographic change in industrial countries an 
increasing prevalence of AKs can be observed. Predominantly elderly male patients 
and people with fair skin types are affected by field cancerisation.[4] In these sun-
damaged skin regions, subclinical and non-visible AK lesions are present adjacent to 
clinical apparent AKs.[5] A recent study reveals that already early AK lesions can 
progress into invasive SCC.[6] Another study showed that thin AKs show the same 
severity of dysplasia and consequently clinical thickness cannot predict 
aggressiveness of AKs.[7] Hence, it is not possible to predict if and which lesion will 
become invasive. Therefore, it is mandatory to monitor and treat the whole field of 
actinic damage.  
However, established clinical classification schemes are based on lesion counts 
assessing the overall thickness of single AKs.[8] To redress these lesion-directed 
classifications recently a new field-directed assessment tool to evaluate AK severity 
on the head has been suggested.[9] As AKs are considered as chronic disease, the 
“actinic keratosis area and severity index” (AKASI) has been developed on the basis 
of other chronic disease monitoring tools such as the psoriasis area and severity index 
(PASI). To calculate AKASI, the head is divided into 4 regions (scalp, face, right/left 
cheek, chin, nose and ear) and each region is estimated for the affected area by AKs. 
AK lesions are evaluated due to characteristic clinical signs such as erythema, 
thickness and distribution. Besides evaluation of disease severity, AKASI objectively 
monitors treatment outcomes of different therapeutic modalities, thus allows 
comparison of the pre and after treatment situation. So far, there is a lack of data 
expressing therapeutic efficacy as AKASI values and analyses outcome thresholds 
such as AKASI improvements of 50%, 75% and 100%. In other chronic skin disease 
such as psoriasis and its assessment tool PASI, these thresholds resemble 
established and comparable evaluation instruments to determine treatment outcome.   
Thus, the aim of the underlying study was to analyse the treatment outcome of patients 
who have undergone photodynamic therapy (PDT) by means of AKASI on the head. 
PDT is a well-established and very effective therapy in patients presenting field 
cancerisation.[10, 11] The mode of action of PDT is based on a photosensitizer, a light 
source for activating the sensitizer and oxygen. A topical prodrug such as 
aminolevulinic acid (ALA) or methyl aminoevulinate (MAL) are applied to the actinically 
damaged field and incubated. Meanwhile neoplastic cells selectively accumulate the 
active photosensitizer protoporphyrin IX (PPXI) owing to their altered metabolism. 
Subsequently, the field is illuminated either by artificial light with a convenient 
wavelength and energy or by natural daylight. Thereby, neoplastic cells of both clinical 
apparent as well as subclinical lesions are selectively destroyed.[12] (Field 
cancerization: from molecular basis to selective field-directed management of actinic 
keratosis. Philipp-Dormston) 
This is the first study to investigate treatment outcome by means of AKASI thresholds 
such as AKASI 100, 75 and 50 as feasible assessment tool.  
 
  
MATERIALS AND METHODS 
Study population 
This retrospective study was performed at the Skin Cancer Centre of the Ruhr-
University Bochum (Bochum, Germany). The study was conducted according to the 
Declaration of Helsinki and approved by the ethics review board of the Ruhr-University 
Bochum (No.: 17-5984-BR). The database of our Skin Cancer Centre was searched 
for patients who have undergone PDT for AKs located on the head. Patients with 
documented AKASI before PDT and at a follow-up visits were included. The follow-up 
period after PDT is typically around three months. We included only patients who have 
been rated by the same physician at both visits (V0 and V1) to avoid inter-rater 
differences. Patients under immunosuppressive therapy or who had a documentation 
of an incomplete PDT (i.e. due to adverse events during intervention such as pain) 
were excluded from this study. All patients included into this study only have 
undergone one PDT between baseline AKASI and follow-up AKASI. Patients who 
received more than one PDT or other interventions (e.g. topical treatment or ablative 
laser treatment) due to AK lesions on the head were not included.  
 
Data assessment 
AKASI is routinely evaluated in all patients with AKs on the head to monitor disease 
severity. These assessments of the study population were performed by two 
investigators (TG, LS). To determine AKASI, the head is divided into four regions 
(scalp, forehead, left and right side of the face [cheek, ear, nose, and chin]. According 
to the extent of each area, the scalp is weighted with 40% and the other three areas 
with 20%. In each region, the percentage of the area affected by AKs is estimated (0-
100% of the separate area), and the severities of three clinical signs (distribution, 
thickness and erythema) of AK were assessed using a quantitative scale from 0 (none) 
to 4 (severe). Due to an algorithm, all sub scores for each region were calculated and 
added to give a total AKASI of the head. This total AKASI can range from 0 to 18. The 
“modified” AKASI was calculated by summing up only sub scores of regions which had 
been treated at both visits, accordingly. The total modified AKASI can have a 
maximum index for 3 regions of 14.4 (scalp included) or 10.8 (scalp excluded). 
 
Photodynamic therapy 
Field-directed PDT was performed with BF-200 ALA (Ameluz®, Biofrontera, 
Leverkusen, Germany) as photosensitizer and BF-RhodoLED lamp (narrow emission 
spectrum of 635nm ± 9nm) as light source. Prior to exposure, the skin was degreased 
and crusts or hyperkeratoses of AK lesions were thoroughly removed by gentle 
curettage. Afterwards, ALA gel was applied to the treatment field and covered with an 
occlusive, light protecting dressing (plastic foil (e.g. 3M Tegaderm™) and aluminium 
foil). After an incubation time of approximately 3 hours, the occlusion was removed 
and topical residuals were wiped off. Subsequently, the treatment field was illuminated 
for 10 minutes at a distance of 5-8cm from the skin surface, resulting in a total light 
dose of 37J/cm². If required, the patients were allowed to cool the skin with cool packs 
after intervention.  
 
Statistical analysis 
Data analysis was performed using the statistical package MedCalc software version 
17.4.4 (Ostend, Belgium). The distribution of data was assessed by the D`Agostino-
Pearson test. If there was normal distribution, data were expressed as mean and 
standard deviation (SD); if not, data were expressed as median and range. Data were 
statistically analysed using the Wilcoxon test for paired samples and the Mann-
Whitney U test for unpaired samples. Data with P-values less than 0.05 were 
considered to be statistically significant. 
.  
RESULTS 
In total, 33 patients with a mean (standard deviation) age of 72.8 (8.1) years were 
included in this study. The majority of patients presented Fitzpatrick skin type II 
(93.9%) and were male (84.8 %). 60.6% of the study population had a positive history 
of at least more than one topical treatment of their AKs. The median AKASI at baseline 
visit was 3.8 (1-7.8) and the median follow-up period was 96 days (70-161). Further 
demographic and clinical characteristics are shown in table 1.  
Overall, 32 (97.0 %) patients showed a reduction and 1 (3.0%) patient an increase of 
AKASI at the follow-up visit compared to the baseline visit. The median (range) 
absolute difference was 2.6 (-1.6-5.4) and relative 73.7% (-34.8-100.0%). The 
Wilcoxon test showed highly significant differences (P < 0.0001) between both visits. 
(Fig 1a). 14 (42.4%) patients showed an AKASI 100 (complete clearance), 16 (48.5%) 
an AKASI 75 and 24 (72.7%) an AKASI 50, respectively. Subgroup analysis of the 32 
patients with AKASI reduction offered a median (range) value of 75.3% (13.6-100.0%). 
Subgroup analysis of patients with a positive history of at least more than one 
intervention and treatment naïve patients showed a median AKASI difference of 61.1% 
(-34.8-100.0%) and 100.0% (13.6-100.0%), respectively (Fig 2). The Mann-Whitney 
U test showed significant differences between the AKASI changes in these two groups 
(P = 0.0302). (Fig 3)  
Analysis of modified AKASI (only areas which were treated was summed up) show a 
median (range) reduction of 80.8% (-8.7-100.0%). The Wilcoxon test presented highly 
significant differences (P < 0.0001) between both visits (Fig 1b). 16 (48.5%) patients 
showed an AKASI 100 (complete clearance), 19 (57.6%) an AKASI 75 and 25 (75.8%) 
an AKASI 50, respectively.      
DISCUSSION 
Current clinical classification systems for AKs are based on the evaluation of single 
lesions and mainly restricted to the clinical criteria thickness of individual lesions.[13] 
As it has been demonstrated that neither thickness of AK lesions predict its 
aggressiveness nor the clinical appearance correlate with the underlying histologic 
grading, a field-directed monitoring tool is highly demanded.[7, 14] The new 
quantitative assessment tool AKASI provides the possibility to compare evaluated 
discrete AKs and areas of field cancerisation on the head. This is the first study to 
investigate the treatment outcome in patients who have undergone PDT on the head 
using AKASI and new defined thresholds such as AKASI 100, 75 and 50.  
This study demonstrated an overall median AKASI improvement of 73.3%. Until there 
are further studies using AKASI data of treatment outcome, these values are hard to 
compare with common endpoints of clinical trials of AK therapies. Many trials 
exclusively rely on a clinical count of single AK lesions. But even experienced 
dermatologists show marked heterogeneity when conducting lesion counts.[15] 
Efficacy endpoints for AK therapy studies are usually defined as “patient complete 
clearance rate” (PCCR) or as “lesion complete clearance rate” (LCCR) but no 
graduated response reflecting area of disease has been reported to date. PCCR can 
be compared with an AKASI improvement of 100% (AKASI 100). The study showed 
an AKASI 100 in 42.4% of patients, which reveals a slightly less effective outcome 
compared to three randomized controlled trials (RCT) conducted with equivalent 
requirements concerning photosensitizer, narrow band light source and PDT protocol. 
These trials showed PCCR of 78%[16], 53%[17] and 62%[18] after one PDT after 12 
weeks of follow-up. This difference can be based on the fact that the PCCR just 
evaluates AK lesions within the treated field and not the entire head. In contrast, the 
standard AKASI takes all lesions of the whole head into account. Moreover, an AKASI 
100 can only be achieved in patients who presented AKASI sub scores solely in 
regions of the head which were undergoing an intervention. To overcome this problem, 
only sub scores of regions which had been treated were summed up to calculate a 
“modified” AKASI. The modified AKASI 100 of the treatment area was 48.5%. It still 
shows lower complete clearance rates in this analysis, which might be due to different 
factors: non RCT, done in daily routine, AKASI differs in general from PCCR, more 
clinical characteristic signs of AK for assessing AKASI might be more sensitive for 
evaluating minor AK residuals. It is questionable if it will be necessary to compare 
these measures in the future once AKASI is used more widely. 
In contrast to the rest of the study population, one patient presented an increased 
standard AKASI of 34.8% and modified AKASI of 8.7%, respectively. There might be 
several reasons for this effect: The patient had a long follow-up period of 120 days. 
Moreover, the patient developed AKs in a non-treated area, which was covered by the 
modified AKASI. Nevertheless, the AKASI of the scalp presented slightly higher at 
follow-up than at the baseline visit. Obviously, this patient appears refractory to PDT 
and/or shows high recurrence rates requiring continuous monitoring as well as more 
frequent AK treatments.   
AKASI is a more differentiated assessment tool with comparable and graduated 
values. Assessment of treatment modalities which do not provide high PCCRs, as 
seen after PDT, benefit from a better graduated evaluation tool. Thus, AKASI can be 
used to precisely monitor therapy regimes.  
The rationale of evaluating a complete lesion clearance in a chronic skin disease such 
as AKs must be questioned. To determine “time-to-relapse” is a better characteristic 
of therapeutic efficacy in a highly chronic disease such as AK.[19] Additionally, field-
directed measurements are needed to assess the efficacy of treatment approaches 
addressing field cancerisation. This study demonstrated AKASI and especially its 
thresholds such as AKASI 100, 75 and 50 to be a very feasible and easy-to use tool 
in daily clinical routine. These parameters could be also assigned as targets in clinical 
trials.  
Interestingly, the difference of treatment outcome in treatment naïve patients and 
patients who has received at least one or more interventions prior to the recorded PDT 
was striking, although in a small study sample. Treatment naïve patients had 
significantly better outcomes than patients with a treatment history while there were 
no significant differences of AKASI at baseline in both groups. One hypothesis could 
be that patients presenting recurrent disease may be more refractory to treatment 
modalities as a whole. If this effect should be reproducible further studies with larger 
populations and other treatment approaches are mandatory. 
Limitations of our study are the retrospective design and the small number of patients 
included. Moreover, the median AKASI at baseline visit of 3.8 ranges between mild-
to-moderate diseases when compared to the pivotal results.[9] Further studies should 
provide a broader range of disease severity in patients with AKs.  
In conclusion, AKASI is a feasible tool to monitor treatment outcomes in patients with 
field cancerisation on the head. In analogy to other chronic skin disease such as 
psoriasis, AKASI 100, 75 and 50 worked out as easy-to apply and comparable 
assessment approach.  
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TABLE LEGEND 
Table1. Demographic and clinical characteristics (N=33) 
Characteristic n (%) 
Sex 
 Male 
 Female 
 
28 (84.8) 
5 (15.2) 
Age, years 72.8 (8.1)a 
Skin Type (Fitzpatrick) 
 I 
 II 
 III - V 
 
2 (6.1) 
31 (93.9) 
0 (0) 
UV Exposure (increased) 
 leisure activities 
 occupational 
24 (72.7) 
23 (95.8)* 
1 (4.2)* 
History 
 median time since AKs first diagnosed, years 
 treatment naïve patients 
 history of at least > 1 treatment of AKs 
  ablative intervention (e.g. curettage, laser) 
  photodynamic therapy 
  DFS 
  5-FU/SA 
 skin cancer history (invasive) 
 
3 (0-15)b 
13 (39.4) 
20 (60.6) 
16 (80.0)* 
14 (70.0)* 
4 (20.0)* 
1 (5.0)* 
19 (57.6) 
Follow-up, days 96 (70-161) b 
 
AK: actinic keratosis;  
DFS: 3% diclofenac sodium in 2.5% hyaluronic acid gel;  
5-FU/SA: 0.5% %-Fluorouracil in 10% salicylic acid (topical solution) 
a Data are mean (standard deviation);  
b Data are median (range);   
* % referring to absolute value of next upper category in this row;  
  
FIGURE LEGEND 
  
 
Fig 1. 
Box-and-Whisker Plot concerning the differences in AKASI prior and after treatment. 
Wilcoxon test shows highly significant differences (P < 0.0001) between AKASI at 
baseline visit (V0) and at the follow-up visit (V1) for both the standard AKASI (a) and 
the modified AKASI (b) (only treated areas were summed up). 
  
 Fig 2. 
Differences of AKASI when compared baseline to follow-up visits.  
Treatment naïve patients (n=13; 39.4%) illustrated as blue columns and patients who 
had received any intervention (n=20; 60.1%) are illustrated as red columns. 
Differences between standard AKASI (a) and modified AKASI (only treated areas 
were summed up) (b). 14 (42.4%) patients when using the standard AKASI (a) and 
16 (48.5%) patients using the modified AKASI (b) showed a complete clearance at 
follow-up visit.   
 Fig. 3. 
Box-and-Whisker Plot concerning the AKASI changes between baseline and follow-
up visit comparing treatment naïve patients and patients who had received any 
intervention. Mann-Whitney U test shows significant differences (P = 0.0302) 
between both groups. 
Orange °: Outlier > less than 3/2 times of lower quartile 
 
